Hormones & Emotional Health

https://www.womensinternational.com/blog/hormones-and-emotional-health/

Hormones and Emotional Health

Adapted from Moods & Emotions a Connections e-Book
A publication of Women’s International Pharmacy

hormones and emotional healthEmotional health is inseparably linked to our hormones. Hormones are powerful substances, with even small quantities able to produce profound effects on health. Moods may be affected by many factors, including:

  • Social and physical environment
  • Diet
  • Exercise
  • Sleep patterns

These factors are also connected to hormones, which regulate the brain’s response system and thereby determine moods. When hormonal conditions are unbalanced, emotions may become “out of whack.”

Sex Hormones, Mood Fluctuations, and Women’s Mental Health

Sex hormones play an important regulatory role in the sense of well-being. From puberty through menopause, women experience a continuous cycle of hormonal fluctuations that affect brain chemistry and, by extension, their moods. This physiological fact of life may partially explain why “depression and anxiety disorders are 2-3 more times more common in women than men,” according to Dr. Elizabeth Lee Vliet.

There is a “previously unrecognized connection between declining hormone levels in perimenopausal women and the high incidence of depression and anxiety disorders,” Dr. Vliet states. She reported on research conducted at Rockefeller University, which indicated that sex hormones are the most potent chemical signals affecting the brain. Changes in the levels of these hormones influence neurotransmitters (such as dopamine and serotonin), which in turn affect moods.

Dr. Vliet also reported on a Yale study, which concluded that hormone therapy over a six-month period appeared to result in an improvement in all categories of perimenopausal symptoms, including:

  • Depression
  • Anxiety attacks
  • Sleep disturbances
  • Short-term memory problems

Mood Changes and Estrogen Imbalance

Estrogen levels have a domino effect on brain chemistry and moods. Aside from estrogen’s many roles in sexual and developmental health, it is also known to be a neuro-stimulant with anti-depressive effects. Dr. Phyllis Bronson states that

“high levels of estrogen produce an imbalance in the system that aggravates or causes symptoms of tension and anxiety.”

Most women tend toward either estrogen dominance or estrogen deficiency, yet a woman will often experience both high and low levels due to hormonal fluctuations relative to her “normal” estrogen level. For instance, normal fluctuations occur during premenstrual syndrome (PMS), while perimenopause causes irregular fluctuations. During these fluctuations, women may experience mixed symptoms as their hormonal balance shifts.

Some women with high estrogen levels may be predisposed to anxiety and panic attacks. On the other hand, low levels of estrogen can lead to episodes of depression. Mood changes associated with a woman’s declining estrogen levels tend to respond well to estrogen therapy; upon receiving treatment, women often report feeling more alert and energetic.

Anxiety and Progesterone Deficiency

The estrogen-progesterone ratio may be the key to properly treating mood disorders. A study by Dr. Bronson found that “a deficiency of progesterone is clearly implicated as a primary factor in mid-life anxiety patterns.” She observed that when estrogen levels were high and progesterone levels low, patients “would exhibit extreme rage, followed by [a] conciliatory, self-defeating demeanor.”

The largest concentration of progesterone receptors is in the limbic area of the brain. This is the center of emotion and is also called the “area of rage and violence” by animal physiologists. Progesterone has a calming effect on the brain, suggesting that its deficiency may lead to anxiety.

Progesterone for PMS, Postnatal Depression, and Menopausal Mood Swings

Premenstrual syndrome and postnatal depression both may occur with a sudden drop in progesterone and may include considerable anxiety. Dr. Katharina Dalton found that these conditions may be effectively treated with progesterone, especially if administered before symptoms develop. For PMS, she suggested supplementing with progesterone from ovulation until menstruation; for preventing postnatal depression, she recommended beginning progesterone therapy immediately after delivery, tapering off until menstruation returns.

Dr. Bronson agrees that progesterone may be an effective treatment for anxiety in perimenopausal women. However, she found higher doses (specifically, 400-600mg daily administered on the skin) to be more effective, with most of her patients reporting significant improvements in emotional health. To achieve the best results in progesterone therapy, both Dr. Bronson and Dr. Dalton’s findings emphasize the importance of using bioidentical progesterone instead of synthetic progestins.

Stress and Thyroid Hormones

The thyroid gland produces several different hormones that have powerful and far-reaching consequences to health. The primary thyroid hormones are thyroxine (T4) and triiodothyronine (T3). These respond to pituitary thyroid-stimulating hormone (TSH) as part of the body’s complex system that regulates endocrine gland secretions.

Thyroid hormones affect every cell in the body in one way or another, including the parts of the body that regulate emotions. Thyroid deficiency inhibits the brain’s neurotransmitters, potentially leading to depression. Thyroid hormones also influence blood glucose levels and the release of stress hormones, two contributors to mood fluctuation.

Insulin, Glucose, and Dietary Factors in Mood Fluctuations

Dr. Dalton noticed a correlation between aggressive, emotional outbursts and blood sugar levels while treating women suffering from PMS. When asked about the time of day or circumstances immediately preceding such outbursts, her patients frequently reported that they occurred later in the morning after missing breakfast, or the evening while preparing a meal (especially if that was occurring later than usual). Many women also reported confusion or forgetfulness during the time surrounding these outbursts.

Paying careful attention to what and when you eat is important to emotional health. In Depression-Free for Life, Dr. Gabriel Cousens identifies foods according to a glycemic index, comparing their impact on blood sugar and mood. For example, eating foods that are high on the glycemic index (such as white flour products, refined and sweetened cereals, and candy bars) should be avoided, as they tend to cause “wild swings in blood sugar, a high followed by a low.”

Other Substances Affecting Mood

Many other hormones, amino acids, and nutrients also affect moods, making difficult to diagnose mood disorders because each individual’s biochemistry has unique needs. We are still learning about how these substances work together to influence emotions. For example:

  • Either too little or too much of the hormone melatonin can lead to depression,
  • People with depression also often have elevated cortisol levels
  • Amino acids (such as glutamine) can affect the neurotransmitters
  • Nutrients such as vitamin B6 and other trace minerals also play an important role in regulating our moods

Conclusion

Because moods are complex, with a wide variety of possible causes or combinations of factors, symptoms of mood disorders may vary significantly from one person to the next and from one day to the next. The common approach of prescribing mind-altering medications may not be the best answer for everyone, particularly if any possible underlying hormonal imbalances are not addressed. However, emotional as well as physical health is a vital contributor to our quality of life, so it’s important to continue exploring how hormones affect mental and emotional well-being to help develop effective treatments for each patient’s needs.

https://www.syracuse.com/health/2019/12/after-four-painful-years-a-cny-womans-mystery-illness-finally-solved.html

After 4 painful years, CNY woman’s mystery illness finally traced to rare tick-borne bacteria

Rare tick borne disease ravaged young woman’s health

“It was like the flu, but for only four days straight,” recalled Allyn, 22, of Skaneateles. “They would test for strep, they would test for mono, and everything would be negative. We thought it was just some weird virus.”

Every few months, the fever returned and disappeared after four days. Until the fall of 2017, when Allyn was a junior at Colgate. This time, the fever stayed, and brought along fatigue and excruciating pain in her joints and muscles.

“You know when you have the flu and your body aches? It was like that times a million,” said Allyn, who was a runner in high school. “I was an extreme athlete, and I couldn’t walk up my stairs to my room anymore. We could tell something was terribly wrong.”

The quest to understand what was wrong, and how to cure it, has consumed Allyn’s life. Since that first fever, Allyn has suffered severe migraines, tingling in her arms and legs that felt like bugs crawling beneath her skin, extreme fatigue, heart palpitations, shortness of breath so constricting that she gasped for air after a flight of stairs, inability to concentrate, and anxiety attacks that convinced her she was dying.

Allyn has seen neurologists, Lyme disease specialists, acupuncturists and chiropractors. She’s been diagnosed with strep throat, chronic fatigue syndrome and Lyme disease. She took dozens of supplements and antibiotics, drank celery juice every morning for four months, and even shut herself inside a claustrophobic hyperbaric chamber in Florida.

Nothing worked.

No one could understand what had turned a star high school athlete into a young woman so sick she couldn’t climb the 10 stairs to her childhood bedroom, or why she wasn’t getting better.

“Those are the darkest days, when you’re trying everything and nothing is working,” said Allyn’s mother, Meg O’Connell. “As a parent you want to shake the doctors and say, ‘You have to take care of my child right now!’”

Finally, this summer, Allyn got a definitive answer. She was diagnosed as one of the first two people in Central New York to contract an emerging tick-borne disease called miyamotoi.

Miyamotoi is so new that, unlike Lyme disease, it doesn’t have a common name, but is referred to simply the species of the bacterium that causes it. It’s in the same genus as the Lyme bacterium, but is more closely related to a group of diseases known as tick-borne relapsing fever.

Tick populations are increasing in Upstate New York, and they are bringing debilitating disease to tens of thousands of people. If it wasn’t bad enough that deer ticks already carried six bacteria and viruses, they and miyamotoi have now evolved to add a new weapon to the arsenal.

Miyamotoi infections were first found in humans in 2011 and confirmed in the Northeast in 2013. Scientists are still studying how it’s transmitted, and many doctors are unfamiliar with the disease, said Brian Leydet, a professor and tick expert at SUNY College of Environmental Science and Forestry, in Syracuse.

“That’s what’s terrifying about it: knowing so little about it, and it’s in our back yard,” Leydet said.

Like many people suffering from tick-borne diseases, Allyn doesn’t remember being bitten. She suspects she picked up the tick while hiking or running trails, and that it hid beneath her long blond hair. Ticks seek out hard-to-see places on the body, like the scalp or behind the knees, and then attach to the skin for 24 to 48 hours, sucking blood and disgorging pathogens.

Allyn also doesn’t remember the date of the first fever, but she lucidly recalls the day the illness took over her life: Oct. 6, 2017, a date she mourns each year. She was walking down the long hill from Colgate to the village of Hamilton when she was overcome with pain and massive fatigue.

“I had to sit down because I didn’t think I could walk the rest of the way home,” she recalled. “I was just having shooting pain all through my muscles and knees and elbows. It felt like everything was breaking in my body.”

She couldn’t focus enough to drive, so her parents brought her home to Skaneateles. She saw a nurse practitioner in Syracuse whom Allyn had worked for, Carolyn Christie-McAuliffe. She drew 30 vials of blood, Allyn recalled.

Allyn returned to Colgate, hoping it was just a case of mononucleosis that would go away so she could finish her junior year. Then the test results came in. The first one, Allyn recalled, counted the markers of inflammation in her body.

“The normal range is about 40 to 60. Mine was 800,” she said. “Carolyn called me and said, ‘You have to go home immediately. Something is really wrong.’”

Allyn took a medical leave from Colgate and returned home yet again. Three days later McAuliffe called with a diagnosis: Lyme disease. There was something odd about the test results, though, that would later become an important clue. While the initial screening test was positive for Lyme, the confirmatory test, called the Western blot, was abnormal, but negative for Lyme, Allyn said.

Allyn went on a four-week course of doxycycline, the standard regimen for Lyme patients. She only felt worse; now the disease was enveloping her brain in a fog.

“I would wake up every morning and not remember what I did,” she recalled. “I’d be watching a TV show I’d been watching for years and I wouldn’t know what was happening. I couldn’t read because I couldn’t concentrate, and I couldn’t really understand words. Most of the days I would lay awake in bed staring at the wall.”

The shattering knee and elbow pain returned. She had “horrible migraines.” She was short of breath and her heart started skipping beats. Her legs and arms tingled with pins and needles. Sitting home alone, Allyn developed paranoia and panic attacks, calling her parents in the middle of the day to say she was dying.

O’Connell remembers her own pain watching her daughter’s.

“It’s just so sad to see someone struggle for two-plus years,” said O’Connell, executive director of the Allyn Foundation. “When you have an ill child, you just want to take that burden from them. You ask, ‘Why couldn’t that have happened to me instead?’”

O’Connell had joined the CNY Lyme and Tick-Borne Disease Alliance. At an early meeting of the alliance, O’Connell met Dr. Kris Paolino, a new physician at Upstate Medical University who specialized in Lyme cases. Paolino, an infectious disease specialist, had helped develop vaccines for Ebola and malaria at the Walter Reed Army Institute of Research in Washington, D.C.

“I happened to say to him that my daughter has Lyme and we can’t get rid of these fevers,” O’Connell recalled. “He said, ‘Make an appointment and come see me.’”

At that first appointment, Allyn recounted her frustrating and painful journey.

“The main thing I try to do is to listen to the patient’s story first,” said Paolino, hired in 2016 as part of Upstate’s battle against the growing threat of tick-borne disease. “In many cases you’re trying to figure out what’s real and what’s not.”

As Allyn’s story unfolded, Paolino noted the clues that raised doubt about the Lyme diagnosis: the relapsing fevers, the neurological symptoms, and that ambiguous Western blot test.

Those suggested miyamotoi. Another round of tests confirmed it.

“I’m not sure if she had ever had Lyme,” Paolino said. “I think it was probably miyamotoi all this time.”

It’s not hard to understand why doctors would suspect Lyme over miyamotoi. The abnormal Western blot test result after a positive Lyme test can be confounding, and miyamotoi is almost unheard of. Just 10 cases of miyamotoi were reported to the state health department from 2001 to 2016, compared to nearly 80,000 cases of Lyme disease.

Paolino said he has now four miyamotoi patients.

“I think there’s probably more people that are undiagnosed than we think,” he said. “It is a fairly new emerging pathogen in the region.”

Paolino prescribed an intense regimen of intravenous antibiotics for Allyn. First doctors inserted a thin tube that ran from Allyn’s upper right arm to her heart. Every night for seven weeks, she said, she spent a half hour pumping two syringes of the antibiotic ceftriaxone into the tube.

The treatment seems to be helping, Allyn and O’Connell said.

“As Dr. Paolino said, ‘Don’t go out and run a marathon yet,’ but we have been really encouraged,” O’Connell said. “She has not had a fever, her blood work is better, her glands are not swollen. She can take longer walks. It will still be another six to 12 months to build up her body because all of it’s been through, but I would say we’re hopefully optimistic.”

No one knows yet if Allyn is cured, what damage the years of treatments might have caused, or if her symptoms will linger even if the bacteria are gone. Paolino said there’s reason for optimism because relapsing fever diseases similar to miyamotoi can be cured by antibiotics. Miyamotoi is so new, however, there’s little research on how patients fare if the disease has been left untreated for years.

“The longer the symptoms are present, you see more damage to the nerves and more damage to the joints that could be more of an irreversible process,” Paolino said. “The hope is that she’ll continue to feel well and she won’t relapse, but I don’t have a definitive answer.”

Fatigue remains a constant presence, Allyn said, but she is slowly regaining strength. She can take her 8-month-old German shepherd, Oaklie, for two walks a day now. She has been attending Colgate part-time, and can do homework in the morning before she gets too tired.

“I’ve gotten a little bit better, but how much better will I get?” she wonders.

It’s time, she said, to find out. On Saturday, she and her boyfriend moved to Boulder, Colorado, where Allyn has an aunt and uncle. She plans to complete her Colgate degree in education and cellular neuroscience by taking her final three classes at the University of Colorado. She’s not ready for a 9-to-5 job, and doesn’t know when she will be, but she hopes to start part-time in a café or bakery. And as she gets stronger, Allyn hopes to put on skis and hiking boots again.

“Life is so short and you could get sick any day,” she said. “Why not go for a hike or go skiing?”

__________________

For more:  https://madisonarealymesupportgroup.com/2018/08/17/borrelia-miyamotoi-found-to-occur-nationwide-in-japan/

https://madisonarealymesupportgroup.com/2018/02/15/b-miyamotoi-in-ca-ticks-for-a-long-time/The following article explains that Borrelia Miyamotoi is not new to California.  

First considered nonpathogenic, it wasn’t even reported until 2011 in Russia.  http://www.nejm.org/doi/full/10.1056/NEJMc1215469  Diagnosis relies on PCR testing during acute infection and two-tiered testing for Lyme will not pick it up. 

It is not a reportable illness so prevalence is pure conjecture.  

Dr. Horowitz states clinicians should be vigilant for clinical pictures that look like viral infections such as high fever, headache, and muscle and joint pain.  

In publications, only 16% of patients presenting with BMD were seropositive for IgG and/or IgM antibody to B. miyamotoi rGlpQ, so PCR should also be considered in patients with a history of tick bites and appropriate clinical manifestations.

This is also an important reminder that new strains and species are being discovered continually, so nothing about Tick Borne Illness should be set in stone and open minds are a must.

https://madisonarealymesupportgroup.com/2018/02/14/borrelia-miyamotoi-in-ca-serodiagnosis-is-complicated-by-multiple-endemic-borrelia-species/ (Study found here)

https://www.lymedisease.org/lyme-sci-study-finds-lots-b-miyamotoi-california-ticks/  

 

https://pediatrics.aappublications.org/content/early/2019/12/15/peds.2019-3447

Identification, Evaluation, and Management of Children With Autism Spectrum Disorder

Susan L. Hyman, Susan E. Levy, Scott M. Myers and COUNCIL ON CHILDREN WITH DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS

Abstract

Autism spectrum disorder (ASD) is a common neurodevelopmental disorder with reported prevalence in the United States of 1 in 59 children (approximately 1.7%). Core deficits are identified in 2 domains: social communication/interaction and restrictive, repetitive patterns of behavior. Children and youth with ASD have service needs in behavioral, educational, health, leisure, family support, and other areas. Standardized screening for ASD at 18 and 24 months of age with ongoing developmental surveillance continues to be recommended in primary care (although it may be performed in other settings), because ASD is common, can be diagnosed as young as 18 months of age, and has evidenced-based interventions that may improve function. More accurate and culturally sensitive screening approaches are needed. Primary care providers should be familiar with the diagnostic criteria for ASD, appropriate etiologic evaluation, and co-occurring medical and behavioral conditions (such as disorders of sleep and feeding, gastrointestinal tract symptoms, obesity, seizures, attention-deficit/hyperactivity disorder, anxiety, and wandering) that affect the child’s function and quality of life. There is an increasing evidence base to support behavioral and other interventions to address specific skills and symptoms. Shared decision making calls for collaboration with families in evaluation and choice of interventions.  This single clinical report updates the 2007 American Academy of Pediatrics clinical reports on the evaluation and treatment of ASD in one publication with an online table of contents and section view available through the American Academy of Pediatrics Gateway to help the reader identify topic areas within the report.

___________________

**UPDATE June, 2022**

‘I Never Had a Single Unvaccinated Patient with Autism’ — Dr. Ben Tapper

For more by Dr. Roseann,a Pediatric Mental Health Expert and Therapist:  https://drroseann.com/new-autism-guidelines/

Excerpt:

Key Findings from the AAP Autism Guidelines

There were many important findings from the AAP Autism guidelines, but here are some additional key ones.

  • The pediatric health care provider is a resource for information and should collaborate with families
  • That children should be formally and regularly screened for Autism as early as possible.
  • Conduct developmental and behavioral observations during all well visits with children, developmental screening at the 9-, 18-, and 30-month visits, and standardized screening of patients for Autism spectrum disorder (ASD) at 18 and 24 months old.
  • Girls may have lesser intensity of symptoms and fewer externalizing behaviors and therefore may be under diagnosed.
  • When developmental concerns are identified, pediatricians should refer children to early intervention (0-3 years of age) or school services to initiate services.
  • Constipation is common in Autism
  • Pediatricians often see young children with severe food selectivity and sleep problems who are later diagnosed with ASD
  • Individuals with ASD are at increased risk for seizures.
  • Almost 16% of young children with ASD have a head circumference greater than the 97th percentile
  • Intervention for children either diagnosed with Autism or even before a formal diagnosis, if they are at-risk, should start as soon as possible.
  • The research shows that the earlier intervention begins, the better their outcomes as they get older.
    There needs to be better identification of co-occurring health conditions now associated with ASD including, ADHD, OCD, anxiety and  sleep and intestinal disorders, seizures, etc.
    That families should consider performing genetic testing that may help better understand the type of Autism a child has, which could affect what type of interventions the child is provided.
  • Children with ASD need evidence-based services to address social, academic and behavioral needs at home and school, with access to appropriate pediatric and mental health care, respite services and leisure activities.
    There is a need for a combination of developmental and behavioral approaches, as well as parent-mediated therapies.
  • At school age, social skills should be addressed through pragmatic language therapy, teaching play and interaction with peers.
  • Wandering is a major behavioral and health risk issue and should be addressed through anticipatory guidance throughout the lifespan.
  • Addressing GI and feeding issues is important
  • Families should be supported to work on transitions to post-secondary education, work and adult health providers
  • Pediatricians need to inform patients and families about the evidence for interventions and give referrals to organizations and providers that can see these children quickly

https://madisonarealymesupportgroup.com/2019/07/08/autism-affecting-up-to-1-in-36-children-in-america/

https://madisonarealymesupportgroup.com/2019/01/07/the-vaccine-debate-top-government-expert-states-vaccines-can-cause-autism-in-some-children/

https://madisonarealymesupportgroup.com/2018/06/15/canadian-data-more-autism-where-vaccine-coverage-is-highest/

https://madisonarealymesupportgroup.com/2017/09/19/autism-aluminum-adjuvant-link-corroborated/

https://madisonarealymesupportgroup.com/2017/10/26/clinical-trial-shows-most-kids-with-autism-are-not-born-with-it/

https://madisonarealymesupportgroup.com/2016/12/08/mercury-and-autism/

https://www.boothbayregister.com/article/collins-smith-s-bill-combat-lyme-and-other-tick-borne-diseases-ready-be-signed-law

Collins, Smith’s bill to combat Lyme and other tick-borne diseases ready to be signed into law

Thu, 12/19/2019 – 4:00pm

Washington, D.C.— U.S. Senators Susan Collins (R-ME) and Tina Smith (D-MN) announced that legislation they authored to improve research, prevention, diagnostics, and treatment for tick-borne diseases passed the Senate today, Dec. 19, as part of the appropriations package. The legislation now heads to the President’s desk to be signed into law.

The Kay Hagan Tick Act unites the effort to confront the alarming public health threat posed by Lyme disease and other tick-borne diseases, which have risen exponentially from approximately 30,000 cases in 2003 to an estimated 450,000 last year.  Senators Collins and Smith renamed the bill in honor of former Senator Kay Hagan, who passed away on October 28th, 2019, due to complications from the tick-borne disease known as the Powassan virus.

In Maine alone, there were approximately 1,400 new cases of Lyme disease in 2018, a sharp increase from the 752 cases in 2010.  Far too many Americans with Lyme disease experience a complex diagnostic odyssey that takes months or even years, while suffering severe and debilitating symptoms.  In addition to the physical and emotional toll that Lyme disease takes, it is also expensive.  Medical costs of Lyme disease are estimated at $1.3 billion per year. When accounting for indirect medical costs, including loss of work, the annual costs balloon to $75 billion per year.

“Congress’ passage of the Tick Act is a major victory for the hundreds of thousands of Americans who contract Lyme and other tick-borne illnesses each year.  I am grateful for the countless advocates who shared their struggles with these diseases and conveyed the urgent need for this comprehensive, bipartisan bill,” said Senator Collins.  “With a national effort the Tick Act would establish, we can slow the spread of these devastating tick-borne illnesses and protect our health.”

“I was misdiagnosed by 23 doctors and specialists to the tune of $250,000 before getting an official diagnosis and proper treatment,” said Paula Jackson Jones, president and co-founder of Midcoast Lyme Disease Support & Education. “Enacting the Tick Act that Senator Collins introduced will provide a lifeline not only to patients but to medical providers. With funding available for research and education, we can get medical providers on the same page not only with improved diagnostic tools but better, more effective treatment options for their patients. With the Tick Act, and Senator Collins’ support in Washington, we can stem the growing threat of tick-borne disease.”

“Lyme is a frustrating and debilitating disease, but it’s a problem we can solve,” said Bonnie Crater, co-founder and board member at Center for Lyme Action.  “What is needed is dedicated and sustained effort by the federal government to address this growing public health threat.  Senators Collins and Smith’s legislation, the Kay Hagan Tick Act is a wonderful first step and is supported by more than 150 Lyme foundations and associations around the United States.”

“Lyme disease and other tick-borne pathogens continue to have significant impacts on public health in Maine and throughout much of the United States. The advancement of The Kay Hagan Tick Act signals a commitment from Congress to tackle the threats associated with ticks and to dedicate resources to managing tick-borne diseases on a national scale. This coordinated approach, focusing on research and education, will be critical in reducing the severe health and financial burdens associated with tick-borne diseases,” said James F. Dill, PhD, Pest Management Specialist and Coordinator, Diagnostic and Research Lab at the University of Maine Cooperative Extension.

“All of us at Global Lyme Alliance extend our heartfelt thanks to Senators Susan Collins and Tina Smith for their dedication to changing the outcome for suffering patients. It has been a long-haul for many of them, especially the kids who were forced to grow up with this poorly diagnosed and treated medical illness. Patients need real solutions, which the Kay Hagan Tick Act will bring!” said Scott Santarella, CEO, Global Lyme Alliance.

“My life was forever changed at age 6 when I was bitten by a tick the summer after first grade,” said 15-year-old Olivia Goodreau, founder of the LivLyme Foundation and TickTracker.  “Children are especially vulnerable to tick borne illnesses, but everyone is at risk. I am so grateful to Senator Susan Collins, her staff, the amazing Lyme advocates, and all those who’ve fought for passage of the Kay Hagan Tick Act. It will save lives by raising awareness and supporting early detection, diagnosis and treatment.”

“I was diagnosed with Lyme Disease the summer of 1986 when I was 14-years-old. Since then, my life has never been the same. I developed Bell’s palsy that paralyzed half my face, a heart murmur, and many other symptoms.  To this day, I continue to fight this disease,” said Heather Hearst, Founder of Maine-based Project Lyme and Advisory Board Member of the Bay Area Lyme Foundation.  “Over the years, I have watched Lyme grow from something that was rare and unknown to a threat that has affected thousands of Mainers, many of whom now suffer from chronic health issues. With the Kay Hagan Tick Act, we can finally put an end to the suffering and slow the spread of tick-borne diseases. I am so grateful to Senator Collins, Senator Smith, and the bipartisan coalition that worked together to make this a national priority”

Using a three-pronged approach, the Tick Act would:

1. Require the Department of Health and Human Services (HHS) to develop a National Strategy.  This would help expand research, improve testing and treatment, and coordinate common efforts across federal agencies including with DOD, USDA, EPA, the VA, and the Departments of Interior and Homeland Security

2. Reauthorize Regional Centers of Excellence in Vector-Borne Disease for five years at $10 million per year.  Funding for these centers, which was allotted in 2017, expires in 2021.  These Centers have led the scientific response against tick-borne diseases, which now make up 75 percent of vector-borne diseases in the U.S.  There are five centers located at universities in New York, California, Florida, Texas, and Wisconsin.

3. Authorize CDC Grants at $20 million per year that would be awarded to State Health Departments to improve data collection and analysis, support early detection and diagnosis, improve treatment, and raise awareness.  These awards would help states build a public health infrastructure for Lyme and other tick and vector-borne diseases and amplify their initiatives through public-private partnerships.

In September, Senator Collins, the Chairman of the Aging Committee, convened a field hearing at the University of Maine Cooperative Extension Diagnostic and Research Laboratory Tick Lab in Orono, where experts and witnesses discussed the critical need to pass the Tick Act.

In 2016, Congress took a critical step forward with the enactment of the 21st Century Cures Act, which created a federal Tick-Borne Diseases Working Group.  This Working Group released its first report in November 2018, which created several recommendations for next steps. With the findings of this report in mind, this legislation puts key recommendations into practice.

The Tick Act is supported by more than 155 organizations, including the Center for Lyme Action, the Entomological Society of America, National Association of Vector-Borne Disease Control Officials, the National Association of County and City Health Officials, Midcoast Lyme Disease Support & Education Organization in Maine, the Northeast Regional Center for Excellence in Vector Borne Diseases, the LivLyme Foundation, the Global Lyme Alliance, and The Avril Lavigne Foundation.

Senators Collins and Smith’s Tick Act was cosponsored by 32 Senators including Senators Shelley Moore Capito (R-WV), Richard Blumenthal (D-CT), Cindy Hyde-Smith (R- MS), Christopher Murphy (D-CT), John Boozman (R-AR), Margaret Hassan (D-NH), Angus King (I-ME), Mike Braun (R-IN), Bernie Sanders (I-VT), Cory Gardner (R-CO), Diane Feinstein (D-CA), Thom Tillis (R- NC), Elizabeth Warren (D-MA), Richard Burr (R-NC), Chuck Schumer (D-NY), Johnny Isakson (R-GA), Patty Murray (D-WA), Kirsten Gillibrand (D-NY), Tammy Baldwin (D-WI), Jeanne Shaheen (D-NH), Bob Menendez (D-NJ), Josh Hawley (R-MO), Tom Cotton (R-AR), Debbie Stabenow (D-MI), Bill Cassidy (R-LA), Bob Casey (D-PA), Michael Bennet (D-CO), Gary Peters (D-MI), and Chris Van Hollen (D-MD).

_________________

https://www.c-span.org/video/standalone/?c4840579/user-clip-rep-chris-smith-tick-act-passage”>http://https://www.c-span.org/video/standalone/?c4840579/user-clip-rep-chris-smith-tick-act-passage  Watch Video Here

Rep. Chris Smith on TICK Act Passage

For more:  https://madisonarealymesupportgroup.com/2019/09/10/maines-senator-collins-holds-field-hearing-on-tick-act/

 

 

https://www.practicalpainmanagement.com/resources/news-and-research/high-level-psychiatric-disorders-found-individuals-chronic-pain

High Level of Psychiatric Disorders Found in Individuals with Chronic Pain

December 16, 2019
Depression, anxiety, and other emotional distress are common in this population.

A PPM Brief

Psychiatric problems significantly affect somatic (body) disorders, which can make treatment difficult and affect prognosis negatively. In some studies, rates of psychiatric disorders in patients with chronic pain have been shown to be higher than the general population.1 One recent study2 evaluated comorbid psychiatric disorders in patients with chronic pain to examine the effects of sociodemographic details and the level of somatic sense perception on disease severity…..(See link for article)

_________________

**Comment**

Important quote:

“Although the mechanisms of the relationship between chronic pain and psychiatric disorders are not fully understood, effective management of both pain intensity and comorbid psychiatric conditions is necessary for the quality of life of patients,” they concluded.

This makes complete sense.  As a patient, I found depression coincided with how I felt physically.  They worked in tandem.  The worse I felt physically, the worse I felt mentally.  I highly doubt I’m alone.  Also, due to the fact mainstream medicine is still in a coma regarding all things tick-borne, family and friends often take the side of the CDC/IDSA that we are all making it up and are nuts.  Isolation, disbelief, and abuse does not help one’s mental outlook!

The medical profession is part of the problem.

For more:  https://madisonarealymesupportgroup.com/2019/04/18/ketamine-reduces-depression-related-behaviors-in-mice-limits-bb-in-vivo-relieves-chronic-pain/

https://madisonarealymesupportgroup.com/2018/11/06/acupuncture-beats-injected-morphine-for-pain-groundbreaking-study/

More on pain management:  https://madisonarealymesupportgroup.com/2018/10/08/thc-vs-cbd-for-pain-the-differences-interactions/

https://madisonarealymesupportgroup.com/2018/01/24/medical-marijuana-for-lyme-a-doctors-perspective/